![](/images/graphics-bg.png)
Rimonabant : From RIO to Ban
Joint Authors
Ghatei, Mohammad A.
Sam, Amir H.
Salem, Victoria
Source
Issue
Vol. 2011, Issue 2011 (31 Dec. 2011), pp.1-4, 4 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2011-07-06
Country of Publication
Egypt
No. of Pages
4
Main Subjects
Abstract EN
Endocannabinoid antagonism as a treatment for obesity and the metabolic syndrome became a hugely anticipated area of pharmacology at the start of the century.
The CB1 receptor antagonist Rimonabant entered the European mass market on the back of several trials showing weight loss benefits alongside improvements in numerous other elements of the metabolic syndrome.
However, the drug was quickly withdrawn due to the emergence of significant side effects—notably severe mood disorders.
This paper provides a brief overview of the Rimonabant story and places the recent spate of FDA rejections of other centrally acting weight loss drugs entering Phase 3 trials in this context.
American Psychological Association (APA)
Sam, Amir H.& Salem, Victoria& Ghatei, Mohammad A.. 2011. Rimonabant : From RIO to Ban. Journal of Obesity،Vol. 2011, no. 2011, pp.1-4.
https://search.emarefa.net/detail/BIM-471863
Modern Language Association (MLA)
Sam, Amir H.…[et al.]. Rimonabant : From RIO to Ban. Journal of Obesity No. 2011 (2011), pp.1-4.
https://search.emarefa.net/detail/BIM-471863
American Medical Association (AMA)
Sam, Amir H.& Salem, Victoria& Ghatei, Mohammad A.. Rimonabant : From RIO to Ban. Journal of Obesity. 2011. Vol. 2011, no. 2011, pp.1-4.
https://search.emarefa.net/detail/BIM-471863
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-471863